Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus

J Infect Dis. 2014 May 1;209(9):1479-84. doi: 10.1093/infdis/jit636. Epub 2013 Nov 22.

Abstract

Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.

Keywords: Staphylococcus aureus; adjuvant; cellular immunity; mucosal; nanoparticle; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Antibodies, Neutralizing / blood
  • Bacterial Load / immunology
  • Female
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / immunology
  • Immunoglobulin G / blood
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Nanoparticles / administration & dosage
  • Staphylococcal Infections / immunology
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / prevention & control*
  • Staphylococcal Vaccines / administration & dosage*
  • Staphylococcal Vaccines / chemistry
  • Staphylococcal Vaccines / immunology
  • Staphylococcus aureus / immunology*

Substances

  • Antibodies, Neutralizing
  • Immunoglobulin G
  • Staphylococcal Vaccines